Bausch + Lomb mulls sale, Financial Times reports

Bausch + Lomb (BLCO) is considering a sale as a strategy to disentangle itself from its indebted parent company, a process complicated by opposition from lenders such as Apollo Global (APO), according to Oliver Barnes and Maria Heeter of Financial Times. The eye care division, which was spun off from Bausch Health in 2020, is consulting with Goldman Sachs to gauge interest from potential buyers, according to sources familiar with the situation. Private equity firms are expected to be among the interested parties.